Inmunómica traslacional en neoplasias hematológicas
Heidelberg University
Heidelberg, AlemaniaPublicacions en col·laboració amb investigadors/es de Heidelberg University (25)
2023
-
Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results
EJHAEM, Vol. 4, Núm. 4, pp. 1117-1131
-
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
Nature Communications, Vol. 14, Núm. 1
2018
-
Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network
Leukemia, Vol. 32, Núm. 7, pp. 1542-1560
2017
-
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology, Vol. 28, pp. iv52-iv61
-
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment
Cancer Cell, Vol. 31, Núm. 3, pp. 396-410
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
-
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
The Lancet Oncology, Vol. 17, Núm. 8, pp. e328-e346
-
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials
Leukemia and Lymphoma, Vol. 57, Núm. 12, pp. 2833-2838
2015
-
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051
2014
-
Combination of International Scoring System 3, highlactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death
Journal of Clinical Oncology, Vol. 32, Núm. 20, pp. 2173-2180
-
European perspective on multiple myeloma treatment strategies in 2014
Oncologist, Vol. 19, Núm. 8, pp. 829-844
-
IMWG consensus on risk stratification in multiple myeloma
Leukemia, Vol. 28, Núm. 2, pp. 269-277
-
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
The Lancet Oncology, Vol. 15, Núm. 12, pp. e538-e548
2012
-
European perspective on multiple myeloma treatment strategies: Update following recent congresses
Oncologist, Vol. 17, Núm. 5, pp. 592-606
2011
-
Consensus recommendations for standard investigative workup: Report of the International Myeloma Workshop Consensus Panel 3
Blood
-
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. Melphalan-prednisone in the phase III VISTA trial in multiple myeloma
European Journal of Haematology, Vol. 86, Núm. 5, pp. 372-384
-
Multiple myeloma treatment strategies with novel agents in 2011: A European perspective
Oncologist, Vol. 16, Núm. 4, pp. 388-403
-
Treatment of relapsed and refractory multiple myeloma in the era of novel agents
Cancer Treatment Reviews, Vol. 37, Núm. 4, pp. 266-283
2010
-
Current multiple myeloma treatment strategies with novel agents: A European perspective
Oncologist, Vol. 15, Núm. 1, pp. 6-25
2009
-
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline
British Journal of Haematology, Vol. 144, Núm. 6, pp. 895-903